TapewireFind a company

person · Reporting owner

Harvey Brian Nicholas

Disclosed activity across 2 companies

Tapewire entity
55604
SEC CIK
0001519432

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Adicet Bio, Inc.ACET · Entity 6860Chief Financial OfficerMarch 25, 2026March 27, 2026
Radius Health, Inc.RDUS · Entity 124173Sr. VP and CFOApril 25, 2017April 27, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adicet Bio, Inc.

Report date March 25, 2026 · Filed March 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2036-03-24Direct43,361 Reported balance After 2026-03-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-25 · Grant · Acquired 43,361 · Balance 43,361

F1: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Radius Health, Inc.

Report date April 25, 2017 · Filed April 27, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect76,189 Reported balance After 2017-04-25 transaction · row 1
1 source row

Row 1 · 2017-04-25 · Exercise / conversion · Acquired 39,616 · Balance 76,189

Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2018-05-08Direct0 Reported balance After 2017-04-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-04-25 · Exercise / conversion · Disposed 27,778 · Balance 0

F1: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from May 8, 2008 until April 24, 2014.

F2: 75% of the shares subject to the option vested on May 8, 2008, and the remaining 25% of the shares subject to the option vested in twelve equal quarterly installments with the first quarterly installment vesting on October 1, 2008.

Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2018-12-03Direct0 Reported balance After 2017-04-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-04-25 · Exercise / conversion · Disposed 11,838 · Balance 0

F3: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from December 3, 2008 until April 24, 2014.

F4: The shares subject to the option vested in sixteen equal quarterly installments with the first quarterly installment vesting on January 1, 2009.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from May 8, 2008 until April 24, 2014.

F2: 75% of the shares subject to the option vested on May 8, 2008, and the remaining 25% of the shares subject to the option vested in twelve equal quarterly installments with the first quarterly installment vesting on October 1, 2008.

F3: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from December 3, 2008 until April 24, 2014.

F4: The shares subject to the option vested in sixteen equal quarterly installments with the first quarterly installment vesting on January 1, 2009.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 25, 2026 Filed Mar 27, 2026 20:14 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 43,361 $0.00 Strike: $6.81 $0.00
Disclosure

SEC source: 0001519432-26-000002 · ownership.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,361

Underlying: Common Stock · 43,361 shares

Expires 2036-03-24

F1 · derivative.exercise_date: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Read SEC document
January 24, 2026 Filed Jan 27, 2026 21:43 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 546 $8.44 $4,608.24
Disclosure

SEC source: 0001193125-26-024746 · ownership.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,145

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

F2 · balance_after: Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 21:39 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 324,040 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0000950170-25-013591 · ownership.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,040

Underlying: Common Stock · 324,040 shares

Expires 2035-01-30

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Read SEC document
January 24, 2025 Filed Jan 28, 2025 21:20 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 8,752 $0.92 $8,067.59
Disclosure

SEC source: 0000950170-25-009827 · ownership.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,048

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 374,829 $0.00 Strike: $2.53 $0.00
Disclosure

SEC source: 0000950170-24-070628 · ownership.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,829

Underlying: Common Stock · 374,829 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Read SEC document
January 24, 2024 Filed Jan 27, 2024 00:08 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 288,022 $0.00 Strike: $2.40 $0.00
Disclosure

SEC source: 0000950170-24-008048 · ownership.xml · derivative · entry 3

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,022

Underlying: Common Stock · 288,022 shares

Expires 2034-01-23

F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Read SEC document
January 24, 2024 Filed Jan 27, 2024 00:08 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 26,300 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-008048 · ownership.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,800

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
January 24, 2024 Filed Jan 27, 2024 00:08 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 4,320 $2.40 $10,368.00
Disclosure

SEC source: 0000950170-24-008048 · ownership.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,500

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

Read SEC document
October 02, 2023 Filed Oct 3, 2023 20:22 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 7,096 $1.37 $9,721.52
Disclosure

SEC source: 0001209191-23-051468 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,820

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 176,308 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 9

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,308

Underlying: Common Stock · 176,308 shares

Expires 2033-08-13

F7 · derivative.exercise_date: Prior to August 14, 2024, no shares shall be vested or exercisable under this option. Effective as of August 14, 2024, the following vesting schedule shall apply: 25% of the shares shall have vested and become exercisable on September 17, 2021, with the remaining 75% vesting in thirty-six (36) equal installments on each monthly anniversary following September 17, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. This option was issued to the Reporting Person because his previously awarded option granted under Nasdaq Listing Rule 5635(c)(4) is not eligible for repricing.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 117,200 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 8

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,200

Underlying: Common Stock · 117,200 shares

Expires 2033-01-23

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 Disposition to issuerStock Option (Right to Buy) · Derivative 117,200 $0.00 Strike: $9.05 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 7

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 117,200 shares

Expires 2033-01-23

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 6

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-06

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 Disposition to issuerStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $15.52 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 5

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2032-01-06

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 28,200 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 4

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,200

Underlying: Common Stock · 28,200 shares

Expires 2031-02-11

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on February 12, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 Disposition to issuerStock Option (Right to Buy) · Derivative 28,200 $0.00 Strike: $16.82 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 3

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,200 shares

Expires 2031-02-11

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on February 12, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2031-01-12

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on January 13, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:10 UTC Adicet Bio, Inc. ACET · Entity 6860 Disposition to issuerStock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $13.27 $0.00
Disclosure

SEC source: 0001209191-23-046100 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires 2031-01-12

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on January 13, 2022, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Read SEC document
January 24, 2023 Filed Jan 26, 2023 21:07 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 117,200 $0.00 Strike: $9.05 $0.00
Disclosure

SEC source: 0001209191-23-005043 · doc4.xml · derivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,200

Underlying: Common Stock · 117,200 shares

Expires 2033-01-23

F2 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates.

Read SEC document
January 24, 2023 Filed Jan 26, 2023 21:07 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 26,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005043 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,916

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
October 04, 2022 Filed Oct 4, 2022 21:21 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 7,096 $14.22 $100,905.12
Disclosure

SEC source: 0001209191-22-052380 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,816

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

Read SEC document
August 04, 2022 Filed Aug 9, 2022 00:27 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 4,696 $18.25 $85,702.00
Disclosure

SEC source: 0001209191-22-044902 · doc4.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,912

Read SEC document
August 04, 2022 Filed Aug 9, 2022 00:27 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-044902 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,608

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
February 14, 2022 Filed Feb 17, 2022 02:33 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 4,696 $14.27 $67,011.92
Disclosure

SEC source: 0001209191-22-010479 · doc4.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,608

Read SEC document
February 14, 2022 Filed Feb 17, 2022 02:33 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-010479 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,304

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
January 28, 2022 Filed Feb 2, 2022 01:42 UTC Adicet Bio, Inc. ACET · Entity 6860 Tax withholdingCommon Stock 4,696 $11.69 $54,896.24
Disclosure

SEC source: 0001209191-22-006134 · doc4.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,304

Read SEC document
January 28, 2022 Filed Feb 2, 2022 01:42 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006134 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,000

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
January 07, 2022 Filed Jan 11, 2022 21:49 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy · Derivative 125,000 $0.00 Strike: $15.52 $0.00
Disclosure

SEC source: 0001209191-22-002900 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-06

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates.

Read SEC document
October 01, 2021 Filed Oct 5, 2021 21:10 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-059569 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Read SEC document
February 12, 2021 Filed Feb 18, 2021 02:12 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 28,200 $0.00 Strike: $16.82 $0.00
Disclosure

SEC source: 0000899243-21-007028 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,200

Underlying: Common Stock · 28,200 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

Read SEC document
January 13, 2021 Filed Jan 15, 2021 21:30 UTC Adicet Bio, Inc. ACET · Entity 6860 GrantStock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $13.27 $0.00
Disclosure

SEC source: 0000899243-21-002189 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2031-01-12

F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of the Vesting Start Date and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company.

Read SEC document
April 25, 2017 Filed Apr 27, 2017 20:58 UTC Radius Health, Inc. RDUS · Entity 124173 Exercise / conversionStock Option (Right to buy) · Derivative 11,838 $0.00 Strike: $2.74 $0.00
Disclosure

SEC source: 0001209191-17-028532 · doc4.xml · derivative · entry 3

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,838 shares

Expires 2018-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from December 3, 2008 until April 24, 2014.

F3 · shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from December 3, 2008 until April 24, 2014.

F4 · derivative.exercise_date: The shares subject to the option vested in sixteen equal quarterly installments with the first quarterly installment vesting on January 1, 2009.

F3 · derivative.underlying_shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from December 3, 2008 until April 24, 2014.

Read SEC document
April 25, 2017 Filed Apr 27, 2017 20:58 UTC Radius Health, Inc. RDUS · Entity 124173 Exercise / conversionStock Option (Right to buy) · Derivative 27,778 $0.00 Strike: $2.74 $0.00
Disclosure

SEC source: 0001209191-17-028532 · doc4.xml · derivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,778 shares

Expires 2018-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from May 8, 2008 until April 24, 2014.

F1 · shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from May 8, 2008 until April 24, 2014.

F2 · derivative.exercise_date: 75% of the shares subject to the option vested on May 8, 2008, and the remaining 25% of the shares subject to the option vested in twelve equal quarterly installments with the first quarterly installment vesting on October 1, 2008.

F1 · derivative.underlying_shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from May 8, 2008 until April 24, 2014.

Read SEC document
April 25, 2017 Filed Apr 27, 2017 20:58 UTC Radius Health, Inc. RDUS · Entity 124173 Exercise / conversionCommon Stock 39,616 $2.74 $108,547.84
Disclosure

SEC source: 0001209191-17-028532 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 20, 2017 Filed Mar 22, 2017 16:44 UTC Radius Health, Inc. RDUS · Entity 124173 Exercise / conversionStock Option (Right to Buy) · Derivative 23,416 $0.00 Strike: $2.05 $0.00
Disclosure

SEC source: 0001209191-17-022322 · doc4.xml · derivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,416 shares

Expires 2017-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from July 12, 2007 until April 24, 2014.

F1 · shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from July 12, 2007 until April 24, 2014.

F2 · derivative.exercise_date: Twenty-five percent of the options vested on December 1, 2007, twenty-five percent of the options vested in twelve equal quarterly installments with the first quarterly installment vesting on January 1, 2008, and the remaining 50% vested upon the completion of certain milestones.

F1 · derivative.underlying_shares: The exercise price and number of derivative securities was adjusted to reflect stock splits that occurred from July 12, 2007 until April 24, 2014.

Read SEC document
March 20, 2017 Filed Mar 22, 2017 16:44 UTC Radius Health, Inc. RDUS · Entity 124173 Exercise / conversionCommon Stock 23,416 $2.05 $48,002.80
Disclosure

SEC source: 0001209191-17-022322 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 17, 2017 Filed Feb 22, 2017 16:26 UTC Radius Health, Inc. RDUS · Entity 124173 GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $45.65 $0.00
Disclosure

SEC source: 0001209191-17-013256 · doc4.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2027-02-16

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.